Filing Details
ACURA PHARMACEUTICALS, INC (OTC:ACUR) filed a Form 8-K with the Securities and Exchange Commission on August 20, 2026, disclosing a material event.
8k filedOTC:ACUR
ACURA PHARMACEUTICALS, INC (ACUR) Reports Material Event to SEC
ACURA PHARMACEUTICALS, INC (OTC:ACUR) filed a Form 8-K with the Securities and Exchange Commission on August 20, 2026, disclosing a material event.
At publication ·
What changed
ACURA PHARMACEUTICALS, INC (OTC:ACUR) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- Acura Pharmaceuticals filed a Form 8-K with the SEC on August 20, 2026, disclosing a material event that shareholders should be aware of, though the specific nature of the event is not detailed in this filing notice.
- The company's stock trades at $0.00 with a market capitalization of $33.0K, indicating an extremely small market value.
Market Context
ACURA PHARMACEUTICALS, INC's stock currently trades at $0.00 with a market capitalization of $33.0K. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for ACURA PHARMACEUTICALS, INC's stock.
All SEC filings for ACURA PHARMACEUTICALS, INC are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View ACUR Stock Page
Frequently Asked Questions
Where can I read ACUR's SEC filings?
Browse all filings on our ACUR SEC filings page.
What types of SEC filings does ACURA PHARMACEUTICALS, INC file?
Public companies like ACURA PHARMACEUTICALS, INC file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.